MarketWatch reports possible joint pain relief from GLP-1 weight loss, while doctors flag that losing weight fast can hurt bone quality, especially in older adults.
Recap by typeshit. Full story at MarketWatch on MSN.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Nestlé is building nutrition products for GLP-1 users, and Circana says alcohol volumes are falling while high-protein, smaller-pack foods gain.
A Wake Forest piece looks at GLP-1 medicines through the lens of brain research on motivation and reward.
Loading…